🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The recent FDA accelerated approval of TECELRA marks a significant step forward in the treatment of synovial sarcoma and the broader field of cell therapy for solid tumors. Explore the impact of this milestone & see what it might mean for future therapies. hubs.ly/Q02KbBMQ0

Just touched down in beautiful Barcelona! Ready for ESMO!! #esmo24

New FDAOncology article: The Retrofit: Lessons From Sotorasib's Dosing Conundrum - via Journal of Clinical Oncology. Authors Harpreet Singh, MD PJ Vellanki Rick Pazdur. ascopubs.org/doi/10.1200/JC… #OCEProjectOptimus #OCEPublications

Thrilled to spend my Saturday with friends and colleagues to hear the latest updates on lung cancer 🫁 #DCLung24

Excited to share my latest article: FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-cell Lymphomas! Here I explore the recent FDA approval of Polatuzumab Vedotin and its impact on the treatment landscape for LBCLs. aacrjournals.org/clincancerres/…

New FDAOncology article: The Retrofit: Lessons From Sotorasib's Dosing Conundrum - via Journal of Clinical Oncology. Authors Harpreet Singh, MD PJ Vellanki Rick Pazdur. ascopubs.org/doi/10.1200/JC… #OCEProjectOptimus #OCEPublications

Join Precision’s leadership team at SITC 2024. With 70% of the clinical trials we support being in oncology, our innovative solutions are designed to meet your research needs from discovery through clinical development.

#BostonCEO

New FDAOncology article: The Retrofit: Lessons From Sotorasib's Dosing Conundrum - via Journal of Clinical Oncology. Authors Harpreet Singh, MD PJ Vellanki Rick Pazdur. ascopubs.org/doi/10.1200/JC… #OCEProjectOptimus #OCEPublications

🧬 Breaking down the #KRAS journey in #LungCancer! 🧬 Harpreet Singh, MD of Precision for Medicine discusses dosing lessons learned from the #AcceleratedApproval of #sotorasib for #KRAS-mutated lung cancer, including considerations for future #trial design. Watch here! oncdata.com/kras-story-in-…

Primary efficacy endpoint pattern in pivotal NSCLC trials supporting initial regulatory decision-making (FDA/EMA). U.S. FDA EU Medicines Agency Clinical Cancer Research OncoAlert doi.org/10.1158/1078-0…

Honored to play my part in the approvals of these breakthroughs for patients, as former Director, Division of Oncology 2, FDA starting in November 2019. 💊

Yesterday in London, an FDA delegation led by FDA Oncology Director Dr. Richard Pazdur met w/ reps from 5 patient groups — Cancer Research UK, Cancer52, The Brain Tumour Charity, Myeloma UK, & Independent Cancer Patients' Voice. It was organized by MHRAgovuk's patient & public involvement team.

The U.S. FDA extended the target action date under PDUFA for the BLA seeking the approval of zenocutuzumab in NRG1-positive NSCLC and pancreatic cancer. #lcsm #pancsm onclive.com/view/fda-exten…

Great day for lung cancer care! Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer! #LCSM

The #FDA has issued new guidance on #accelerated approvals and confirmatory trials, aiming to ensure that initial response rates lead to genuine patient benefit. In this video, Harpreet Singh, MD Precision for Medicine shares her insights on this guidance. Watch here! youtu.be/LW1F6yYEVn8?si…

Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology. Guest editorial by Harpreet Singh, MD (Precision for Medicine) cancerletter.com/guest-editoria…

Over 20 years ago FDA directed manufacturers to reformulate pediatric vaccines by removing thimerosal, an ethylmercury-based preservative previously used in multi-dose vials. In response, vaccines like Hib and DTaP shifted to single-dose vials, eliminating need for preservatives

Great presentations on collaborations & barriers in “Call to action” NY Lung Cancer Foundation Summit ⁦IASLC⁩ ⁦Karen Kelly⁩ ⁦Harpreet Singh, MD⁩ #Fred_Hirsch

FDA Oncology Center Director Richard Pazdur, MD, was named the recipient of the AACR 2025 Enduring Impact Award for Transformative Service to Cancer Science and Medicine, for his public service at U.S. FDA over the past 25 years. aacr.org/about-the-aacr…